YOU ARE LEAVING THIS WEBSITE
By clicking this link, you will be leaving the NERLYNX® website and will be redirected to another webpage.« NO, GO BACK YES, LEAVE THIS WEBSITE »
Puma Patient Lynx™ is designed to provide the support you may need throughout your NERLYNX treatment. Access valuable guidance and resources while receiving emails and text that can help you:
Supportive care voucher
In order to best support your experience on NERLYNX, we offer coverage of products used for antidiarrheal treatment.†
This support can be accessed through a voucher, which can be obtained from your healthcare team or from one of the Puma network Specialty Pharmacies. The voucher can be used at any retail pharmacy to provide you up to 3 months FREE supply of product(s) that have been prescribed to you for antidiarrheal treatment.
Please see the voucher for qualifying guidelines and additional utilization instructions.
Nurse call center
Our nurses are available to speak with patients to answer questions about NERLYNX. The call center is open 24 hours a day, 7 days a week for your convenience. For more information call 1-855-816-5421.
†This program benefit is offered based on the findings from the CONTROL trial, which show that using antidiarrheals can help to manage diarrhea that may be caused by NERLYNX.
We’re committed to helping patients have access to NERLYNX. That’s why reimbursement services are available to:
Co-pay support for commercially insured patients
‡Limitations apply. Patient must have commercial insurance. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Puma Biotechnology reserves the right to rescind, revoke, or amend this program without notice. For full terms and conditions, call 1-855-816-5421.Enroll in co-pay support now
The patient assistance program
NERLYNX is provided free to patients who are uninsured and meet certain financial qualifications.
NERLYNX quick start
Eligible patients who are experiencing delays in accessing therapy may be provided with a free 3-week supply of NERLYNX.
Please call our Reimbursement Specialists at 1-855-816-5421 for more information.
If you haven’t gotten your prescription directly from your doctor’s office, you will receive a call from a specialty pharmacy shortly after your doctor submits your prescription. The number may be unrecognizable to you, but this call is important to confirm your prescription.
NERLYNX is available through several specialty pharmacies that offer helpful services, including:
Download a NERLYNX brochure
Your resource to help you get started on treatment with NERLYNX.Brochure SPANISH/ESPAÑOL
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about NERLYNX (ner links)?
NERLYNX® (neratinib) may cause serious side effects, including:
Your healthcare provider may change your dose of NERLYNX, temporarily stop or completely stop NERLYNX if needed to manage your diarrhea.
See "What are the possible side effects of NERLYNX?" for more information about side effects.
What is NERLYNX?
NERLYNX is a prescription medicine used to treat adults who have early-stage breast cancer, which:
It is not known if NERLYNX is safe and effective in children.
Before taking NERLYNX, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines used to decrease stomach acid, called proton pump inhibitors or PPIs, and H-2 receptor antagonists. You should avoid taking these medicines during treatment with NERLYNX.
What are the possible side effects of NERLYNX?
NERLYNX may cause serious side effects, including:
See "What is the most important information I should know about NERLYNX?"
Common side effects of NERLYNX include:
These are not all the possible side effects of NERLYNX.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
For Patient Information, please click here.